Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Published

Journal Article

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

Full Text

Duke Authors

Cited Authors

  • Crawford, J; Becker, PS; Armitage, JO; Blayney, DW; Chavez, J; Curtin, P; Dinner, S; Fynan, T; Gojo, I; Griffiths, EA; Hough, S; Kloth, DD; Kuter, DJ; Lyman, GH; Mably, M; Mukherjee, S; Patel, S; Perez, LE; Poust, A; Rampal, R; Roy, V; Rugo, HS; Saad, AA; Schwartzberg, LS; Shayani, S; Talbott, M; Vadhan-Raj, S; Vasu, S; Wadleigh, M; Westervelt, P; Burns, JL; Pluchino, L

Published Date

  • December 2017

Published In

Volume / Issue

  • 15 / 12

Start / End Page

  • 1520 - 1541

PubMed ID

  • 29223990

Pubmed Central ID

  • 29223990

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0175

Language

  • eng

Conference Location

  • United States